Progression of prostate cancer to neuroendocrine cell tumor

International Journal of Urology

Volumn 8, Issue 8, 2001, Pages 431-436

  Tanaka, Masashi ^a   Suzuki, Yoshio ^a   Takaoka, Katsuyuki ^a   Suzuki, Noriyuki ^b   Murakami, Shino ^c   Matsuzaki, Osamu ^d   Shimazaki, Jun ^e  

^a DIVISION OF REPRODUCTIVE BIOLOGY   (United States)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c RESEARCH AND DEVELOPMENT   (Australia)

^d College of Chemistry and Molecular Engineering ^*  (China)

^e ASAHI GENERAL HOSPITAL   (Japan)

Author keywords

Endocrine therapy resistance; Neuroendocrine cell tumor; Progression; Prostate cancer; Small cell carcinoma

Indexed keywords

CHLORMADINONE ACETATE; CISPLATIN; ESTRAMUSTINE PHOSPHATE; ETHINYLESTRADIOL; ETOPOSIDE; FLUTAMIDE; FOSFESTROL; GONADORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; AUTOPSY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; MULTIMODALITY CANCER THERAPY; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; SMALL CELL CARCINOMA;

AGED; AGED, 80 AND OVER; CARCINOMA, NEUROENDOCRINE; DISEASE PROGRESSION; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 0035572295     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2001.00347.x     Document Type: Article

References (24)

1. Androgen deprivation for prostatic carcinoma: A rationale for choosing components
2. PSA decline is an independent prognostic marker in hormonally treated prostate cancer
3. Hormone resistance in prostate cancer
4. Neuroendocrine differentiation and hormone-refractory prostate cancer
5. Diagnosis and staging of prostate cancer
6. Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging
7. Neural crest origin of the endocrine polypeptide (APUD) cells of the gastrointestinal tract and pancreas
8. Multidirectional differentiation in the normal, hypertrophic, and neoplastic human prostate: Simultaneous demonstration of cell-specific epithelial markers
9. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: A stem cell model
10. Neuroendocrine differentiation in prostatic carcinoma
11. Development of human prostate cancer cells to neu-roendocrine-like cells by interleukin-1
12. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells
13. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: Implications for prostate cancer progression
14. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma
15. Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression
16. The prognostic influence of neuroendocrine cells in prostate cancer: Results of a long-term follow-up study with patients treated by radical prostatectomy
17. Neuroendocrine differentiation in prostate cancer: Enhanced prediction of progression after radical prostatectomy
18. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma
19. Small cell carcinoma of the prostate: Part I. A clinicopathologic study of 20 cases
20. Small cell carcinoma of the prostate: A case report and review of the literature
21. Small cell carcinoma of the prostate: A case report
22. Undifferentiated carcinoma of the prostate with small cell features: Immunohisto-chemical subtyping and reflections on histogenesis
23. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate
24. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors